Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of $1.90 billion. The enterprise value is $1.95 billion.
| Market Cap | 1.90B |
| Enterprise Value | 1.95B |
Important Dates
The next estimated earnings date is Thursday, September 17, 2026, before market open.
| Earnings Date | Sep 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 48.39 million shares outstanding. The number of shares has increased by 1.17% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 48.39M |
| Shares Change (YoY) | +1.17% |
| Shares Change (QoQ) | +1.69% |
| Owned by Insiders (%) | 3.14% |
| Owned by Institutions (%) | 13.59% |
| Float | 33.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 49.59 |
| Forward PS | 53.38 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 50.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.09
| Current Ratio | 1.09 |
| Quick Ratio | 1.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.01 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -10.06% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -102.31% |
| Weighted Average Cost of Capital (WACC) | 7.40% |
| Revenue Per Employee | $382,682 |
| Profits Per Employee | -$281,331 |
| Employee Count | 100 |
| Asset Turnover | 0.48 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Nanobiotix has paid $3,522 in taxes.
| Income Tax | 3,522 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +455.36% in the last 52 weeks. The beta is 0.56, so Nanobiotix's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +455.36% |
| 50-Day Moving Average | 38.62 |
| 200-Day Moving Average | 29.63 |
| Relative Strength Index (RSI) | 47.86 |
| Average Volume (20 Days) | 119,495 |
Short Selling Information
The latest short interest is 84,555, so 0.23% of the outstanding shares have been sold short.
| Short Interest | 84,555 |
| Short Previous Month | 52,503 |
| Short % of Shares Out | 0.23% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.87 |
Income Statement
In the last 12 months, Nanobiotix had revenue of $38.27 million and -$28.13 million in losses. Loss per share was -$0.59.
| Revenue | 38.27M |
| Gross Profit | 38.27M |
| Operating Income | -12.78M |
| Pretax Income | -28.13M |
| Net Income | -28.13M |
| EBITDA | -9.70M |
| EBIT | -12.32M |
| Loss Per Share | -$0.59 |
Balance Sheet
The company has $61.93 million in cash and $111.92 million in debt, with a net cash position of -$49.98 million or -$1.03 per share.
| Cash & Cash Equivalents | 61.93M |
| Total Debt | 111.92M |
| Net Cash | -49.98M |
| Net Cash Per Share | -$1.03 |
| Equity (Book Value) | -99.19M |
| Book Value Per Share | -2.05 |
| Working Capital | 6.16M |
Cash Flow
In the last 12 months, operating cash flow was -$38.05 million and capital expenditures -$612,527, giving a free cash flow of -$38.66 million.
| Operating Cash Flow | -38.05M |
| Capital Expenditures | -612,527 |
| Depreciation & Amortization | 447,441 |
| Net Borrowing | 43.48M |
| Free Cash Flow | -38.66M |
| FCF Per Share | -$0.80 |
Margins
Gross margin is 100.00%, with operating and profit margins of -33.39% and -73.52%.
| Gross Margin | 100.00% |
| Operating Margin | -33.39% |
| Pretax Margin | -73.51% |
| Profit Margin | -73.52% |
| EBITDA Margin | -26.15% |
| EBIT Margin | -33.19% |
| FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.17% |
| Shareholder Yield | -1.17% |
| Earnings Yield | -1.48% |
| FCF Yield | -2.04% |
Analyst Forecast
The average price target for Nanobiotix is $44.38, which is 17.35% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $44.38 |
| Price Target Difference | 17.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 39.36% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of 1.11 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.11 |
| Piotroski F-Score | 1 |